Source comparison
Kisspeptin for PCOS Researchers: Protocol Comparison
Pulsatile Kisspeptin-10 1 nmol/kg SC every 2 hours × 14 days Restore ovulatory cyclicity Rodent models show 60% response rate (DHT-PCOS model) Requires programmable infusion pump or repeated injections; high burden Best for mechanistic studies; not scalable to
This comparison does not assign a generated winner or score.
- Pulsatile Kisspeptin-10
- 1 nmol/kg SC every 2 hours × 14 days
- Restore ovulatory cyclicity
- Rodent models show 60% response rate (DHT-PCOS model)
- Requires programmable infusion pump or repeated injections; high burden
- Best for mechanistic studies; not scalable to human trials
- Single Bolus Kisspeptin-54
- 1–2 nmol/kg IV once
- Induce acute LH surge for ovulation triggering
- Phase 1 human data; safe, well-tolerated
- Single administration simplifies compliance; requires IV access
- Promising for controlled ovarian stimulation protocols; limited data in PCOS specifically
- Kisspeptin Antagonist (Peptide 234)
- Continuous SC infusion 10 nmol/kg/day × 28 days
- Suppress excess LH in hyperandrogenic PCOS
- Preclinical only; no human data
- Aims to block overactive kisspeptin signaling; opposite approach to agonists
- Theoretically sound for hyperresponder phenotype; requires Phase 1 safety validation
- Metformin + Kisspeptin-10
- Metformin 1500 mg/day oral + Kisspeptin-10 0.5 nmol/kg SC weekly
- Improve insulin sensitivity while normalizing GnRH pulsatility
- Combination data from one pilot trial (n=18)
- Addresses both metabolic and reproductive axes; lower kisspeptin dose needed with metformin co-treatment
- Most clinically translatable; combines proven metabolic intervention with targeted neuroendocrine modulation